Format

Send to

Choose Destination
Biomed Pharmacother. 2017 Aug;92:681-689. doi: 10.1016/j.biopha.2017.05.125. Epub 2017 Jun 3.

Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.

Author information

1
Ocean College, Zhejiang University, Hangzhou, 310058, China.
2
Department of Zoology, Kohat University of Science and Technology (KUST), K.P.K 26000, Pakistan.
3
Faculty of Pharmacy, Gomal University D.I.Khan, K.P.K 29050, Pakistan.
4
Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego-92182, USA.
5
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: Hassan13@zju.edu.cn.

Abstract

Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.

KEYWORDS:

FDA approved drugs; GBM chemotherapy; Natural anti-glioma; Novel anti-glioma; Synthetic anti-glioma

PMID:
28582760
DOI:
10.1016/j.biopha.2017.05.125
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center